Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

ResMed Q4 2024 Adj. EPS $2.08 Beats $2.07 Estimate, Sales $1.232B Beat $1.217B Estimate

Author: Benzinga Newsdesk | August 01, 2024 04:07pm
ResMed (NYSE:RMD) reported quarterly earnings of $2.08 per share which beat the analyst consensus estimate of $2.07 by 0.48 percent. The company reported quarterly sales of $1.232 billion which beat the analyst consensus estimate of $1.217 billion by 1.26 percent. This is a 9.80 percent increase over sales of $1.122 billion the same period last year.

Posted In: RMD


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist